Drug Trial Radar · NCT04954859
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
366
Actual
Start
Dec 14, 2021
Primary completion
Jan 24, 2029
Study completion Jan 24, 2029
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jul 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a global multi-center, long-term follow-up study to assess durability of efficacy, as measured by maintenance of treatment response from the parent study, in participants who participated in a previous bepirovirsen study and achieved a complete or partial response. Eligible participants will be enrolled in this study after completing the end of study (EoS) visit in the respective parent bepirovirsen studies (studies B-Clear \[209668: NCT04449029\], B-Together \[209348: NCT04676724\], B-Fine \[212602: NCT04544956\], B-Well 1 \[202009: NCT05630807\], B-Well 2 \[219288: NCT05630820\], and TH HBV ASO-001 \[217023: NCT05276297\]). Participants will be categorized as Not-on-NA, NA-cessated, or On-NA based on their nucleos(t)ide analogue (NA) status in the parent study. No further treatment with bepirovirsen will be administered in this study.
Conditions
- Hepatitis B
Interventions
BepirovirsenDrug
No study drug will be administered in this study. Eligible participants who received prior treatment with bepirovirsen in the parent studies will be included.
PlaceboDrug
No study drug will be administered in this study. Eligible participants who received prior treatment with placebo in the parent studies (209668, 202009, and 219288) will be included to maintain the blind in the still ongoing parent studies.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Not-on-NA participants without loss of parent study primary outcome (PSPO)Time frame: From primary endpoint assessment in the parent study up to Month 57
- Percentage of On-NA participants rolling over from studies 209668 and 209348 without loss of functional cure (FC) after NA-cessation in study 206882Time frame: From Month 3 up to Month 57
- Percentage of On-NA participants rolling over from study 217023 without loss of FC after NA-cessation in study 206882Time frame: From Month 3 up to Month 33
- Percentage of NA-cessated participants rolling over from studies 202009 and 219288 without loss of FC after NA-cessation in the parent studyTime frame: From primary endpoint assessment in the parent study up to Month 33
Locations
161 sites in 29 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Sacramento, California
GSK Investigational Site
San Jose, California
GSK Investigational Site
Colorado Springs, Colorado
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Detroit, Michigan
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Rosario, Argentina
GSK Investigational Site
Santa Fe, Argentina
GSK Investigational Site
La Plata, Buenos Aires, Argentina
GSK Investigational Site
Herston, Queensland, Australia
GSK Investigational Site
Fitzroy, Victoria, Australia
GSK Investigational Site
Campinas, Brazil
GSK Investigational Site
Curitiba, Brazil
GSK Investigational Site
Manaus, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
Vila Mariana, Brazil
GSK Investigational Site
Aracaju, Sergipe, Brazil
GSK Investigational Site
Plovdiv, Bulgaria
GSK Investigational Site
Sliven, Bulgaria
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Varna, Bulgaria
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Victoria, British Columbia, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Beijing, China
GSK Investigational Site
Beijing, China
GSK Investigational Site
Beijing, China
GSK Investigational Site
Chengdu, China
GSK Investigational Site
Chengdu, China
GSK Investigational Site
Chongqing, China
GSK Investigational Site
Fuzhou, China
GSK Investigational Site
Guangzhou, China
GSK Investigational Site
Guangzhou, China
GSK Investigational Site
Guangzhou, China
Showing 40 of 161 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.